| P2093 | author name string | Juliano RL | |
| | Cho M | |
| | Yoo H | |
| | Kole R | |
| | Alahari S | |
| P2860 | cites work | Selecting effective antisense reagents on combinatorial oligonucleotide arrays | Q28240424 |
| | Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset | Q74106138 |
| | Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries | Q74109346 |
| | bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice | Q74165698 |
| | Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits | Q74230827 |
| | Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes | Q74527972 |
| | How to design an antisense oligodeoxynucleotide experiment: a consensus approach | Q74565825 |
| | Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys | Q74771853 |
| | Cellular uptake and intracellular fate of antisense oligonucleotides | Q75294069 |
| | Promise and problems of Bcl-2 antisense therapy | Q73529352 |
| | Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration | Q73731733 |
| | Morpholino antisense oligomers: design, preparation, and properties | Q28243074 |
| | hnRNP proteins and the biogenesis of mRNA | Q29547911 |
| | Pharmacokinetics and biodistribution of a nucleotide-based thrombin inhibitor in rats | Q32058931 |
| | CpG motifs in bacterial DNA trigger direct B-cell activation | Q34307394 |
| | The third helix of the Antennapedia homeodomain translocates through biological membranes. | Q34338497 |
| | Polyamidoamine cascade polymers mediate efficient transfection of cells in culture | Q34347285 |
| | The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism | Q34407499 |
| | Extracellular matrix-dependent tissue-specific gene expression in mammary epithelial cells requires both physical and biochemical signal transduction | Q34719628 |
| | Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide | Q34893888 |
| | Tissue architecture: the ultimate regulator of epithelial function? | Q35212052 |
| | Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice | Q35782543 |
| | Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice | Q35856548 |
| | Electrophoresis in lyotropic polymer liquid crystals | Q35870926 |
| | Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides | Q35935577 |
| | Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies | Q36052460 |
| | Antileukemia effect of c-myc N3'-->P5' phosphoramidate antisense oligonucleotides in vivo | Q36108131 |
| | Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides | Q36684554 |
| | Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence | Q36707669 |
| | Matrix-assisted laser desorption ionization time-of-flight mass spectrometry as a rapid quality control method in oligonucleotide synthesis | Q36850714 |
| | Mechanism of oligonucleotide release from cationic liposomes | Q37255679 |
| | Intracellular distribution of microinjected antisense oligonucleotides | Q37458928 |
| | Inhibition of Herpes Simplex Virus Replication by Antisense Oligo-2'-O-methylribonucleoside Methylphosphonates | Q38289245 |
| | Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures | Q38330348 |
| | Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages | Q38332851 |
| | Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides | Q38333233 |
| | Antisense drug discovery: can cell-free screens speed the process? | Q38335416 |
| | The activity of c-myb antisense oligonucleotide to prevent intimal hyperplasia is nonspecific | Q38338597 |
| | Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors | Q38339481 |
| | Antisense oligonucleotides: is the glass half full or half empty? | Q38341158 |
| | Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake | Q38344442 |
| | Pharmacology of Therapeutic Oligonucleotides | Q38345416 |
| | Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice | Q38347073 |
| | Hepatic distribution and clearance of antisense oligonucleotides in the isolated perfused rat liver | Q38347129 |
| | The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty | Q38347294 |
| | Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. | Q38347812 |
| | Development of targeted delivery systems for nucleic acid drugs | Q38349807 |
| | Pharmacokinetic properties of several novel oligonucleotide analogs in mice | Q38358571 |
| | Progress in antisense oligonucleotide therapeutics | Q38363412 |
| | In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells | Q39720919 |
| | Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus | Q39723515 |
| | Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells | Q40409131 |
| | Current concepts in antisense drug design | Q40827692 |
| | Antisense oligonucleotides as therapeutic agents--is the bullet really magical? | Q40834751 |
| | Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues | Q40878981 |
| | Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development | Q41035037 |
| | Integrin receptor-targeted transfer peptides for efficient delivery of antisense oligodeoxynucleotides | Q41058656 |
| | Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides | Q41102744 |
| | Transformed and immortalized cellular uptake of oligodeoxynucleoside phosphorothioates, 3'-alkylamino oligodeoxynucleotides, 2'-O-methyl oligoribonucleotides, oligodeoxynucleoside methylphosphonates, and peptide nucleic acids | Q41110040 |
| | Intercellular trafficking and protein delivery by a herpesvirus structural protein | Q41133058 |
| | Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression | Q41181451 |
| | Evaluation of adjuvants that enhance the effectiveness of antisense oligodeoxynucleotides | Q41222315 |
| | In vivo studies with antisense oligonucleotides | Q41441257 |
| | Antisense oligonucleotides as therapeutics for malignant diseases. | Q41454086 |
| | Antisense—Protein Kinase A: A Single-Gene-Based Therapeutic Approach | Q41522945 |
| | Advances in Understanding the Pharmacological Properties of Antisense Oligonucleotides | Q41526814 |
| | First- and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies. | Q41543873 |
| | Developing oligonucleotide therapeutics for human leukemia. | Q41543878 |
| | Cell adhesion and drug resistance in cancer | Q41643292 |
| | Phosphorothioate oligodeoxynucleotides: large-scale synthesis and analysis, impurity characterization, and the effects of phosphorus stereochemistry | Q41651516 |
| | Pharmacokinetics of oligonucleotides | Q41651532 |
| | Role of pharmacokinetics and metabolism in drug discovery and development | Q41689728 |
| | Perspectives in antisense therapeutics | Q41735644 |
| | A good antisense molecule is hard to find | Q41736928 |
| | Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides | Q41940139 |
| | Selective inhibition of alpha1B-adrenergic receptor expression and function using a phosphorothioate antisense oligodeoxynucleotide. | Q42541956 |
| | Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides | Q42808622 |
| | Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression | Q42828535 |
| | On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites | Q44721997 |
| | Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey | Q45085148 |
| | In VivoMetabolic Profile of a Phosphorothioate Oligodeoxyribonucleotide | Q45216750 |
| | Cellular and Molecular Barriers to Gene Transfer by a Cationic Lipid | Q45868044 |
| | Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer | Q45885575 |
| | 2'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. | Q46002868 |
| | An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery | Q46233956 |
| | Genetic medicine--when will it come to the drugstore? | Q46432165 |
| | In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. | Q46561257 |
| | An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice | Q46725691 |
| | Identification and partial purification of human double strand RNase activity. A novel terminating mechanism for oligoribonucleotide antisense drugs | Q46741260 |
| | Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). | Q46767395 |
| | Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides. | Q46877752 |
| | Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs (review). | Q47614304 |
| | Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation | Q48004626 |
| | Radiolabeling of methylphosphonate and phosphorothioate oligonucleotides and evaluation of their transport in everted rat jejunum sacs | Q50761096 |
| | A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth | Q53463575 |
| | Cationic polyhexylcyanoacrylate nanoparticles as carriers for antisense oligonucleotides. | Q54566936 |
| | DNA antisense therapy for asthma in an animal model | Q59060753 |
| | Analysis of antisense oligonucleotides by capillary electrophoresis, gel-slab electrophoresis, and HPLC: a comparison | Q71476214 |
| | Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides | Q72779505 |
| | Intracellular routing and inhibitory activity of oligonucleopeptides containing a KDEL motif | Q73128199 |
| | Crohn's trial shows the pros of antisense | Q73137222 |
| | Characterization of oligonucleotide metabolism in vivo via liquid chromatography/electrospray tandem mass spectrometry with a quadrupole ion trap mass spectrometer | Q73166321 |
| | An antisense oligonucleotide on the mouse Shaker-like potassium channel Kv1.1 gene prevents antinociception induced by morphine and baclofen | Q73341899 |
| | Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery | Q73426688 |
| P433 | issue | 4 | |
| P921 | main subject | pharmacodynamics | Q725307 |
| P304 | page(s) | 494-502 | |
| P577 | publication date | 1999-04-01 | |
| P1433 | published in | Pharmaceutical Research | Q7180737 |
| P1476 | title | Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides | |
| P478 | volume | 16 | |